SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (997)7/17/1997 2:56:00 PM
From: JOHN W.   of 6136
 
Dr. Patick completed her presentation with moe compelling evidence from a study with 170 people. MRK is on now. MRK as well as the other PI manufacturers including VRTX, must acknowledge that for PI naive patients must commence therapy with nelf to allow future treatment options if resistance develops to nelf (D30N). The ongoing clinical studies which will be presented by AGPH in September will by then leave no doubt. In the interest of MRK's bottom line, they are willingly causing a health hazzard that will leave people with no further PI options except nelf. Patients that develop resistance to crixivan will respond to nelf, but this should be considered the exception and not the rule.

Everytime a new scip is written for Crixivan instead of Viracept, someone just limited his/her chances significantly for sustained viral suppression. MRK needs to care more about patients and not just their bottom line.

Regards, John.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News